High Dose Rate prostate brachytherapy for Prostate Cancer

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Prostate CancerHigh Dose Rate prostate brachytherapy - Radiation
Eligibility
40 - 80
Male
What conditions do you have?
Select

Study Summary

This trial will offer men with intermediate risk prostate cancer the opportunity to be randomized between low dose rate brachytherapy and high dose rate brachytherapy. Men will also be offered the opportunity to test the aggressiveness of their cancer using Cell Cycle Progression Gene Profile.

Eligible Conditions
  • Prostate Cancer

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Study Objectives

1 Primary · 7 Secondary · Reporting Duration: 5-10 years

0-10 years
Acute and long term toxicity
0-36 months
Quality of Life in the bowel and sexual domains
The difference in Quality of Life in the urinary domain between LDR and HDR brachytherapy.
Time to return to baseline +/- 3 points for the International Prostate Symptom Score
3 years
Histologic Outcome
5-10 years
Biochemical Outcome
baseline
TRUS- MRI fusion
one month
Cell cycle progression score

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

Low dose rate brachytherapy
1 of 2
High dose rate brachytherapy
1 of 2

Active Control

Experimental Treatment

60 Total Participants · 2 Treatment Groups

Primary Treatment: High Dose Rate prostate brachytherapy · No Placebo Group · Phase 3

High dose rate brachytherapy
Radiation
Experimental Group · 1 Intervention: High Dose Rate prostate brachytherapy · Intervention Types: Radiation
Low dose rate brachytherapy
Radiation
ActiveComparator Group · 1 Intervention: Low dose rate prostate brachytherapy · Intervention Types: Radiation

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 5-10 years

Who is running the clinical trial?

British Columbia Cancer AgencyLead Sponsor
163 Previous Clinical Trials
90,070 Total Patients Enrolled
23 Trials studying Prostate Cancer
5,870 Patients Enrolled for Prostate Cancer
Ross Halperin, MDStudy DirectorBritish Columbia Cancer Agency Program Director
1 Previous Clinical Trials
140 Total Patients Enrolled
1 Trials studying Prostate Cancer
140 Patients Enrolled for Prostate Cancer

Eligibility Criteria

Age 40 - 80 · Male Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
References